Emerging roles of sympathetic nerves and inflammation in perivascular adipose tissue by Saxton, SN et al.
Emerging roles of sympathetic nerves and 
inflammation in perivascular adipose 
tissue
Saxton, SN, Withers, SB and Heagerty, AM
http://dx.doi.org/10.1007/s10557­019­06862­4
Title Emerging roles of sympathetic nerves and inflammation in perivascular 
adipose tissue
Authors Saxton, SN, Withers, SB and Heagerty, AM
Type Article
URL This version is available at: http://usir.salford.ac.uk/50230/
Published Date 2019
USIR is a digital collection of the research output of the University of Salford. Where copyright 
permits, full text material held in the repository is made freely available online and can be read, 
downloaded and copied for non­commercial private study or research purposes. Please check the 
manuscript for any further copyright restrictions.
For more information, including our policy and submission procedure, please
contact the Repository Team at: usir@salford.ac.uk.
ORIGINAL ARTICLE
Emerging Roles of Sympathetic Nerves and Inflammation in Perivascular
Adipose Tissue
Sophie N. Saxton1 & Sarah B. Withers1,2 & Anthony M. Heagerty1
# The Author(s) 2019
Abstract
Perivascular adipose tissue (PVAT) is no longer recognised as simply a structural support for the vasculature, and we
now know that PVAT releases vasoactive factors which modulate vascular function. Since the discovery of this function
in 1991, PVAT research is rapidly growing and the importance of PVAT function in disease is becoming increasingly
clear. Obesity is associated with a plethora of vascular conditions; therefore, the study of adipocytes and their effects on
the vasculature is vital. PVAT contains an adrenergic system including nerves, adrenoceptors and transporters. In
obesity, the autonomic nervous system is dysfunctional; therefore, sympathetic innervation of PVAT may be the key
mechanistic link between increased adiposity and vascular disease. In addition, not all obese people develop vascular
disease, but a common feature amongst those that do appears to be the inflammatory cell population in PVAT. This
review will discuss what is known about sympathetic innervation of PVAT, and the links between nerve activation and
inflammation in obesity. In addition, we will examine the therapeutic potential of exercise in sympathetic stimulation of
adipose tissue.
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Abbreviations
BAT Brown adipose tissue
FFAs Free fatty acids
IL-6 Interleukin-6
NA Noradrenaline
OCT3 Organic cation transporter 3
PVAT Perivascular adipose tissue
SNS Sympathetic nervous system
TNF-α Tumour necrosis factor α
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Introduction
Obesity is increasingly prevalent and is currently estimated to
affect around 30% of adults in the UK [1]. Obesity is associ-
ated with a cluster of health conditions known as the metabol-
ic syndrome, including hypertension and type-II diabetes, all
of which may contribute to reduced life expectancy [2, 3]. It is
estimated that obesity costs the UK’s National Health Service
£4.2 billion per year [4], which presents a considerable burden
to society. Therefore, there is a need to transform obese pa-
tients into metabolically fit individuals. One might assume
that the simple solution is weight loss; however, clinical stud-
ies have indicated that most patients will regain weight lost
through diet [5]. This highlights a need for new therapeutic
strategies in place of caloric restriction.
We live in an age of convenience; high-calorie foods are
readily available, with less need to expend energy. As a result
of excess energy intake, adipose tissue depots expand.
However, adipose tissue is not just an energy store and is
actually a highly metabolically active endocrine organ [6–9].
Perivascular adipose tissue (PVAT) surrounds a number of
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peripheral vascular beds and is comprised of dynamic cell
populations in addition to adipocytes, which includes nerves,
stem cells, microvasculature and a plethora of immune cells
[6, 10, 11]. There is a wealth of evidence that PVAT secretes
vasoactive factors, which modulate vascular tone in isolated
arteries [12–14]. Many of these factors are reported to have
anti-contractile effects on resistance arteries, skeletal muscle
arteries and the aorta, reducing peripheral resistance [11,
15–17]. Therefore, these factors are likely to contribute to
modulating blood pressure in vivo [14]. In obesity, where
autonomic dysfunction is known to occur, PVAT becomes
inflamed and its secretory profile becomes dysfunctional
[11, 18]. Loss of PVAT functionmay contribute to the vascular
complications associated with obesity such as hypertension
and type-II diabetes [19–22].
In this review, we will discuss the roles of sympathetic
innervation in adipose tissue phenotype and function, and
highlight the consequences of autonomic dysfunction within
PVAT. In addition, we will cover the inflammatory environ-
ment in obese PVAT, and explore the links between sympa-
thetic innervation and inflammation.
Adipocytes: More than Fat Stores
There are two classical and functionally different types of
adipocytes: white and brown. White adipose tissue (WAT) is
widespread in the body, comprising the majority of visceral,
subcutaneous and perivascular adipose depots, and one func-
tion is to provide support and insulation for the organs and
vessels it surrounds [23]. White adipocytes are most widely
recognised as a form of energy storage, and they contain a
large lipid droplet for storing free fatty acids [24]. Therefore,
it is white adipocytes which proliferate and expand in obesity.
However, the belief that WAT is purely an energy store has
long since passed, and we now know that adipocytes secrete
almost 100 different proteins including vasoactive adipokines
and inflammatory cytokines which play a number of roles
including modulation of vascular tone, insulin resistance and
body weight regulation [23, 25–27]. In addition to this diverse
secretory profile, adipocytes express receptors for a number of
substrates including neurotransmitters, indicating a role for the
nervous system in regulating adipocyte function.
Whilst white adipocytes store energy, brown adipocytes
expend it, and are well known for their role in thermogenesis,
particularly in infants. These smaller adipocytes, with a large
number of mitochondria, produce heat through uncoupled res-
piration [23, 28, 29]. Brown adipose tissue (BAT) depots are
highly vascularised compared to WAT, which allows for effi-
cient dispersal of heat. Since brown adipocytes are associated
with energy expenditure, it has been proposed that brown
adipocytes may confer metabolic improvements in obesity,
where there is an imbalance between energy intake and
expenditure [30, 31]. Indeed in mouse models, BAT trans-
plants have demonstrated the potential usefulness of brown
adipocytes. When BATwas transplanted into the visceral cav-
ity of obese mice, insulin resistance was completely reversed
and whole body metabolism increased, which reduced total
body fat mass [32, 33]. However, whilst BAT is widespread in
the mouse, BAT in humans mostly disappears between infan-
cy and adulthood [34], although functional BAT is present in
the region between the anterior neck and thorax [30]. The
importance of these findings lies in the recently developed
field of adipose tissue ‘beiging’. It is possible to stimulate
white adipocytes to differentiate into a new adipocyte pheno-
type; the beige adipocyte, which bears resemblance to brown
adipocytes in its number of mitochondria, and therefore, its
ability to participate in thermogenesis [35, 36]. This process
can be stimulated by increases in healthy sympathetic stimu-
lation, i.e. exercise, as well as cold exposure and caloric re-
striction [35, 37–39]. The physiological importance of sym-
pathetic nerve-induced beiging will be discussed below.
The composition of PVAT varies with its anatomical loca-
tion [10, 11, 40–43. Mesenteric and aortic PVAT is the most
widely studied. Mesenteric PVAT primarily consists of WAT,
although its adipocytes are relatively smaller than other vis-
ceral adipose depots [44, 45]. Expression of lipolytic genes in
mesenteric PVAT is high; therefore, the rate of both basal and
catecholamine-induced lipolysis is high in this vascular bed
[44, 46]. In addition, expression of vascular endothelial
growth factor is high, which is vital for expansion of adipose
tissues in obesity [47]. Around the thoracic aorta, PVAT con-
sists of BAT, whereas the abdominal aortic PVAT is a mixture
[26, 43, 48]. Interestingly, this change in composition is
thought to be linked to the development of atherosclerosis;
the abdominal aorta is most susceptible to atherosclerosis,
and expression of inflammatory markers in abdominal aortic
mixed PVAT is high [48]. As discussed above, the BAT in
thoracic aortic PVAT could have a protective effect. There
have been some studies on PVAT surrounding coronary arter-
ies. These studies indicate that, like mesenteric PVAT, coro-
nary PVAT consists of small white adipocytes [49]. However,
the secretory profile of coronary adipocytes is different.
Expression of the vasodilator adipokine, adiponectin is low,
and expression of pro-inflammatory factors is high [50]. This
has been linked to development of hypertension and myocar-
dial infarction [51–53].
Sympathetic Innervation of Adipose Tissue
The sympathetic nervous system (SNS) modulates lipolysis of
WAT. Sympathetic denervation will impair lipolysis, and in-
crease WAT expansion [54–57]. Conversely, SNS activation
will increase lipolysis [58]. In addition, this increase in lipol-
ysis can be reduced by β-adrenoceptor inhibition. These
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studies clearly indicate that adipocytes express adrenoceptors
which will respond to sympathetic nerve-derived
catecholamines.
Electrophysiology studies confirm that sympathetic nerves
are present in both WAT and BAT [59, 60], although the de-
gree of activity in response to certain stimuli does vary be-
tween the two types [61]. In particular, SNS activity inWAT is
increased by glucoprivation, cold exposure and food depriva-
tion, increasing lipolysis and release of free fatty acids (FFAs).
Whereas in BAT, only cold exposure will increase nerve ac-
tivity, resulting in increased thermogenesis. Studies using ret-
rograde viral tract tracers have indicated that nerve fibres pres-
ent in adipose tissue originate from the general sympathetic
nerve outflow of the central nervous system [55, 62, 63].
These studies also indicated the presence of sensory nerve
fibres. The function of these sensory nerve fibres and their
interaction with sympathetic nerves is unclear. It is likely that
the sensory nerves sense products of lipolysis, feeding back
onto the SNS in order to regulate lipolysis [62, 64]. However,
a recent study has indicated that sensory nerves may directly
stimulate the release of leptin from PVAT, which has a
vasorelaxant effect on the vasculature [65].
The tight packing of adipocytes has made it difficult to
visualise direct contact between nerves and adipocytes, and
histological studies are conflicting. Studies using markers for
sympathetic nerves agree that they are present in both BAT
and WAT depots, including visceral, subcutaneous and
perivascular depots [19, 66–68]. Whilst most tissues receive
dual autonomic innervation, i.e. sympathetic and parasympa-
thetic, 97–98% of nerves in adipose tissue are sympathetic
[69]. Interestingly, a marker for vascular specific sympathetic
nerves, neuropeptide tyrosine, is negative in BAT, indicating
that adipocytes are innervated by a separate nerve population
to the vasculature [67]. Whilst some studies have indicated a
high degree of direct contact between nerves and adipocytes
[66, 70, 71], others have determined that only 2–3% of adipo-
cytes are directly innervated [68]. Therefore, it remains to be
confirmed if adipocytes are directly innervated, or are
responding to catecholamine spill over.
We have recently confirmed that the anti-contractile effect
of PVAT in vitro is dependent upon sympathetic nerves [19].
Electrical stimulation (activating sympathetic nerves) of small
mesenteric resistance arteries with and without PVAT demon-
strates that PVAT exerts an anti-contractile effect, which can
be abolished using pharmacological sympathetic denervation
of the adipose tissue. Similar effects have been reported in the
superior mesenteric artery, whereas in the aorta electrical stim-
ulation induces a pro-contractile effect [15]. The difference
between the two vascular beds can be explained by the adi-
pose tissue phenotype: mesenteric PVAT comprises WAT,
whereas aortic PVAT is BAT. Interestingly, the anti-
contractile effect of PVAT in the mesenteric bed is absent in
the spontaneously hypertensive rat, indicating the importance
of PVAT function in blood pressure regulation [15]. In addi-
tion, when a greater electrical stimulus is used, mesenteric
PVAT will exert a pro-contractile effect on the vasculature
[72], suggesting that increased nerve activity will alter PVAT
function.
PVAT Contains an Adrenergic System
As discussed previously, catecholamines induce lipolysis in
WAT via adrenoceptors on adipocytes, in particular β3-
adrenoceptors [71, 73]. In BAT, β3-adrenoceptors stimulate
thermogenesis [74]. Previously, these metabolic functions
were thought to be the only roles for adrenoceptors on adi-
pocytes [75]; however, we now know that adipocyte β3-
adrenoceptors regulate vascular tone. In larger conductive
vessels, β3-adrenoceptors are present in the endothelium,
and when stimulated will mediate vasorelaxation [76–78].
However, they are not present in the small resistance arteries
which modulate blood pressure. Despite this, a specific β3-
adrenoceptor agonist induces hypotension in canines and
rodents [79]. Briones et al. [80] demonstrated that this same
agonist will induce vasodilation in small arteries, only when
PVAT is left intact. Similarly, the agonist induces PVAT-
dependent hyperpolarisation of vascular smooth muscle
cells [81]. Recently, using β3-adrenoceptor antagonists,
we have confirmed that β3-adrenoceptors are vital in the
PVAT anti-contractile effect, and that stimulation of β3-
adrenoceptors triggers secretion of the vasodilator
adiponectin from PVAT [19].
It is worth noting that all adrenoceptor subtypes are present
on adipocytes, and they all play a role in modulating lipolysis
(reviewed by Lafontan and Berlan [82]). Whilst β-
adrenoceptors are stimulatory, α-adrenoceptors inhibit lipoly-
sis. However, it appears that only adipocyte β3-adrenoceptor
contribute to the PVAT anti-contractile effect.
The existence of a catecholamine system within adipocytes
was first demonstrated by Pizzinat et al. [83]). This group
reported the expression of monoamine oxidase A and B in
adipocytes, indicating that adipocytes will uptake and
metabolise monoamines such as noradrenaline (NA).
Mesenteric WAT adipocytes [19, 84] and BAT [85] express
organic cation transporter 3 (OCT3). OCT3 is a member of
solute carrier family SLC2AA, and plays a vital role in
extraneuronal transport of neurotransmitters such as NA into
the periphery [86–88]. We have recently shown that OCT3
plays a functional role in PVAT anti-contractile effect, by en-
abling adipocytes to sequester sympathetic nerve-derived NA.
In addition to metabolising NA, it is possible that adipo-
cytes are a source of NA [89]. When denervated aortic BAT
and mesenteric WAT is stimulated with tyramine, the adipose
tissue releases functional NA [89]. However, as discussed
below, PVAT contains a diverse immune cell population,
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many of which can produce NA [90, 91]. Therefore, further
investigation is required to determine if it is the adipocytes
themselves producing NA.
Autonomic Imbalance in Obesity
It is widely accepted that the SNS is pathologically overactive
in obesity [92, 93]. Overactivity has been confirmed in multiple
skeletal muscle studies [94–96], as well as studies of the cardiac
and renal nerves [97]. Most importantly, the degree of SNS
overactivity positively correlates with body fat mass, and varies
with the location of increased adiposity. In particular, SNS ac-
tivity is highest in patients with excessive visceral adipose tis-
sue [98]. The causative mechanisms of SNS overactivity are
not well understood (reviewed by Lemche et al. [99] and Smith
and Minson [92]); however, it is likely due to an imbalance in
the hypothalamic-pituitary axis [100]. Changes in adipokine
secretion will contribute to this imbalance. Leptin in particular
is greatly increased in obesity, and has a stimulatory effect on
the SNS; therefore, it is highly likely that leptin may be one
driver of SNS overactivity in obesity.
One consequence of SNS overactivity in obesity is im-
paired catecholamine-induced lipolysis, which will contribute
to adipocyte hyperplasia and hypertrophy [101–104]. Basal
lipolysis however, is increased [105]. This may be due to
increases in expression of inflammatory cytokines, discussed
further below, which exert a stimulatory effect on lipolysis
[106, 107]. This increase in basal lipolysis will result in an
increase in circulating FFAs, which will contribute to devel-
opment of insulin resistance, glucose intolerance and hyper-
tension through effects on skeletal muscle and the renin-
angiotensin-aldosterone system [108–111]. Studies in first-
degree re la t ives of obese pa t ien ts indica te that
catecholamine-induced lipolysis is impaired in the offspring
of obese patients [112]. This may suggest that impaired lipol-
ysis occurs before expansion of adipose tissues. Indeed some
studies have indicated that SNS overactivity occurs alarming-
ly early in response to a high-fat diet, before significant weight
gain. In rats, only 12 days of a cafeteria diet induces SNS
overactivity [113]. Similar rapid changes in SNS activity have
been reported in humans with small changes in body weight,
and the magnitude of SNS overactivity increases with the
amount of weight gained [114].
With regard to PVAT function, it is possible that SNS over-
activity will contribute to PVAT dysfunction in obesity. In
heart failure patients, SNS overactivity results in
desensitisation and internalisation of β-adrenoceptors [115].
It is possible that a similar effect occurs in adipose tissue, and
SNS overact ivi ty may resul t in β3-adrenoceptor
internalisation in adipocytes, leading to reduced adiponectin
release, and a loss of PVAT anti-contractile function.
However, this has not yet been explored. For a summary of
the potential effects of SNS overactivity in obesity, see Fig. 1.
Obesity-Induced Inflammation of PVAT
Numerous models of obesity, including genetic [116, 117] and
diet-induced [11, 118], demonstrate a loss of the PVAT anti-
contractile effect, which likely contributes to development of
hypertension. However, not all obese patients develop hyper-
tension, and not all hypertensive patients are obese. A key
common feature between obese hypertensives and lean hyper-
tensives is the inflammatory populations in adipose tissue
[119, 120]. PVAT contains a rich population of innate and
adaptive immune cells [121], which is rapidly altered in obe-
sity. In obesity, the increased need for energy storage results in
adipocyte hypertrophy [11]. In addition, catecholamine-
induced lipolysis is impaired [101]; this may be contributory
to changes in catecholamine sensitivity which has been inde-
pendently related to systolic blood pressure changes in a study
of healthy, normotensive patients, and therefore, may have
profound effects in hypertension [122]. Hypertrophy is not
accompanied by increases in vascularisation, leading to hyp-
oxia and subsequent oxidative stress and chronic inflamma-
tion [123, 124].When subjected to hypoxia in vitro, the loss of
PVAT function in obesity can be replicated in small resistance
arteries from mice and rats [11, 18], indicating the importance
of hypoxia-induced changes to the PVAT environment.
Moreover, this loss of function can be reversed in vitro using
antioxidants and cytokine antagonists [11, 18, 125]. One char-
acteristic of hypoxia in obesity is an increase in expression of
pro-inflammatory cytokines such as tumour necrosis factor
alpha (TNF-α) and interleukin-6 (IL-6) [126, 127].
Application of antibodies for these cytokines can reverse
PVAT dysfunction in hypoxia [11]. The role of TNF-α in
hypertension is uncertain; some studies have shown that ele-
vated TNF-α levels have been associated with the develop-
ment of hypertension [128] whereas others using the DOCA-
salt model of hypertension have shown no link [129]. This
may indicate a differing role in different causes of hyperten-
sion. Further to this, there is strong evidence to support a role
for IL-6 in hypertension both from experimental models [130]
and human data [131].
Macrophages represent a large proportion of the immune
cell population in PVAT, and in obesity macrophages are the
main source of TNF-α and IL-6 [132]. Interestingly, loss of
PVAT function in hypoxia can be prevented in the absence of
macrophages [18], indicating the importance of macrophages
in the inflammatory process of PVAT. In lean adipose tissue,
the macrophage phenotype is predominantly M2 macro-
phages (alternatively activated macrophages) which release
anti-inflammatory cytokines such as interleukin-10 [133],
and are a source of catecholamines [90]. However, in obesity,
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there is a phenotypic switch from M2 macrophages to M1
macrophages (classically activated macrophages) [134]. In
addition, macrophage infiltration is increased in both human
and mouse obesity [18, 135]. Further to this, a ‘macrophage-
centric model’ has been proposed to support the interrelated-
ness of neural, renal and vascular contributions to hyperten-
sion (reviewed by Harwani et al. [136],). These studies sug-
gest that it is increased M1 macrophage activation and infil-
tration in obesity which contribute significantly to the in-
creases in pro-inflammatory cytokine expression in obesity.
It is worth noting that adipocyte-derived M1 macrophages
may contribute directly to vascular dysfunction in obesity by
reducing bioavailability of the vasodilator hydrogen sulphide
in the endothelium [137], which has been known to develop
prior to blood pressure changes in the spontaneously hyper-
tensive rat [138].
Eosinophils are present in large numbers in healthy PVAT;
however, levels are decreased in obesity [91]. Interestingly,
the PVAT anti-contractile effect is lost in eosinophil-deficient
mice, which is accompanied by increased blood pressure and
reduced glucose tolerance. We have demonstrated previously
that this phenotype and PVAT function can be rescued by
eosinophil transplant [91], highlighting the importance of eo-
sinophils in regulating PVAT function. Similar to M2 macro-
phages, eosinophils are a source of catecholamines, and are
able to stimulate production of adiponectin and nitric oxide
(NO) via activation of adipocyte β3-adrenoceptors [91].
Studies are emerging that parasitic induced eosinophilia may
Fig. 1 Consequences of SNS overactivity in PVAT. A high-fat diet will
increase adipose tissue mass. In addition, in response to a high-fat diet,
sympathetic nervous system (SNS) activity increased. One consequence
of SNS overactivity is impaired catecholamine-induced lipolysis, which
will contribute to increased adipose mass. It is possible that SNS overac-
tivity may cause desensitisation and internalisation of adipocyte
adrenoceptors. As a result of SNS overactivity, adipose tissue becomes
inflamed and its secretory profile is altered. In particular, leptin secretion
is increased, which will contribute to autonomic imbalance. Secretion of
the vasodilator adiponectin is reduced, which will have direct effects on
the vasculature, and may increase arterial tone. Infiltration of pro-
inflammatory M1 macrophages is increased, which will increase expres-
sion of inflammatory cytokines including tumour necrosis factorα (TNF-
α) and interleukin-6 (IL-6). Expression of anti-inflammatory cytokines is
reduced. Changes to the immune cell populations will contribute to vas-
cular dysfunction
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confer metabolic benefits in obesity. This hypothesis stems
from the low incidence of cardiovascular disease in develop-
ing countries where helminth infections are prevalent [139,
140]. In mice, eosinophilia induced by a helminth infection
demonstrates an increase in M2 macrophage activation, and
has shown promise in improving glucose tolerance in obesity
[141]. These effects may be mediated via interleukin-4 secre-
tion from eosinophils, which has been shown to increase M2
polarisation [142]. IL-4 levels have been seen to be lower in
hypertensive patients compared with control [143], and serum
IL-4 and gene expression levels are reduced in patients with a
particular cholesteryl ester transfer protein Taq1B polymor-
phism, and is associated with hypertension in this group
[144]. However, the direct link between hypertension and eo-
sinophils remains to be fully understood at this stage.
There are a number of other immune cells in PVAT
which may contribute to pathogenesis in obesity, although
their roles in adipose tissue are not well studied.
Neutrophils are present at low levels in healthy PVAT,
and their number is increased in obesity [145], and de-
creased following bariatric surgery [146]. Interestingly,
neutrophil numbers correlate with blood pressure variabil-
ity in lean hypertensive patients [147], indicating a role for
neutrophils in vascular dysfunction. It is likely that their
role in producing a variety of reactive oxygen species
(ROS) is contributory to this observation [148]. Mast cells
follow a similar pattern of expression in adipose tissue to
neutrophils, and mast cell gene deficiency protects against
diet-induced weight gain, and enhances glucose tolerance
[149]. Mast cells are host to a panel of vasoconstrictor
agents which are likely to underpin their contribution to
vascular dysfunction. T and B cells are also increased in
adipose tissue in obesity [150, 151], and both may be im-
plicated in obesity pathogenesis. In a pharmacological
model of hypertension in lean mice, T cell numbers are
increased [152]. Data from lymphocyte-deficient scid mice
implicated an eNOS- and COX-2-dependent pathway
[153]. In diet-induced obese mice, treatment with B cell-
depleting antibodies protects against insulin resistance and
glucose intolerance [151]. All of these studies represent the
importance of adipose tissue immune cell research in un-
derstanding vascular dysfunction in obesity.
It is important to note that expression of adiponectin, one
of the potential adipokines responsible for the anti-
contractile effect in health, has been shown to be reduced
in hypoxia [154]. This decrease in adiponectin would likely
worsen the inflammatory response, as adiponectin inhibits
inflammatory cytokine production [155]. Additionally,
adiponectin receptor 2 plays an important role in
revascularisation following ischaemic injury [156].
Therefore, it is possible that reduced circulating adiponectin
in obesity may prevent vascularisation of increased adipose
depots, leading to hypoxia and inflammation.
The Role of Sympathetic Nerves
in Inflammation
The autonomic nervous system is integral to the inflammatory
reflex [157]. The parasympathetic nerve-mediated cholinergic
anti-inflammatory effect is well studied [158], whereas in
comparison little attention is paid to the role of sympathetic
nerves. Similar to parasympathetic nerves, sympathetic nerves
have an important immunosuppressive role to play [159].
Whereas parasympathetic nerves regulate the number and
function of lymphocytes, sympathetic nerves are involved in
the control of granulocytes, including eosinophils, through
adrenoceptors expressed on the surface of these cells [160].
Adrenoceptors are present on a number of immune cells, in-
cluding splenocytes [161–163], macrophages [162, 164], T
and B cells [165] and, as already mentioned, eosinophils
[91]. Therefore, all of these immune cells will respond to
sympathetic nerve-derived NA. Using retrograde tract tracers,
sympathetic inputs to key components of the immune system
including the thymus, bone marrow and lymph nodes have
been well characterised [41, 166, 167]. Sympathetic input to
lymph nodes is of particular significance in the context of this
review, as PVAT is in close proximity to lymphatic organs,
which likely enables the immune population in PVAT to alter
rapidly in response to need [168]. In response to lipopolysac-
charides, circulating TNF-α is increased, and this increase is
greatly enhanced following sympathetic denervation of the
spleen [163, 169]. Similarly, global sympathetic inhibition
using reserpine elicited a similar enhancement of TNF-α pro-
duction in response to lipopolysaccharides, and in this study,
administration of β-adrenoceptor agonists reduced this en-
hancement of TNF-α production [162]. Macrophages are a
large source of TNF-α, and express adrenoceptors; therefore,
the effects of sympathetic denervation and reserpine on
TNF-α may be mediated via increased macrophage activity.
These studies indicate a clear role for sympathetic nerves in
inflammation; therefore, it is likely that autonomic dysfunc-
tion in obesity may contribute to adipose inflammation
(Fig. 1).
Effects of Exercise on Autonomic Function
and Inflammation
Exercise, which is considered to be a healthy, physiological
form of sympathetic nerve activation, is well known to have
beneficial effects in a number of diseases, including hyperten-
sion, diabetes and tachycardia [170, 171], and there is evi-
dence that these beneficial outcomes may be mediated via
effects on adrenoceptor activity, and on immune cells. In ad-
dition, exercise has been shown to reduce pathological sym-
pathetic nerve activity occurring in obesity [172].
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During exercise, the nutrient and oxygen demands of skel-
etal muscle is increased; therefore, there is a need for an acute
increase in vasodilation to increase blood flow to the muscle
via resistance arteries [173]. During this time, the contractility
of vascular smooth muscle cells is altered [174, 175]. It is
thought that this change in blood flow is controlled locally
by chemical mediators produced by the muscle, red blood
cells and endothelial cells [173, 176, 177]. However, the acute
exercise-induced vasodilation is very rapid, and has been ob-
served within 1 s of commencing exercise [178]. Therefore, it
is likely that there is an initial contribution from the mechan-
ical effect of muscle squeezing the vessels and pushing blood
into the muscle [176, 179, 180]. This will be maintained after
approximately 5 s by vasoactive chemicals. In addition, vas-
cular tone is regulated by the autonomic nervous system, and
during exercise, sympathetic nerve-mediated vasoconstriction
is increased. This action of the nerves will limit vasodilation,
preventing overloading of the heart with blood [181].
Interplay during exercise between sympathetic nerve evoked
vasoconstriction, and chemically induced local vasodilation
results in only moderate changes in blood pressure [173].
Chronic exercise is known to improve cardiovascular func-
tion; including increasing blood flow capacity [173], al-
though, the molecular pathways and their links to the benefi-
cial effects of exercise in disease are still being explored. It is
likely that chronic exercise results in changes in gene expres-
sion and causes adaptations which will increase the efficiency
of the vasculature in responding to the needs of muscle during
exercise [182]. Chronic exercise training has been shown to
increase flow-mediated dilation in large muscle arteries, and
endothelium-dependent dilation in resistance arteries [183,
184]. Multiple studies have suggested that the increase in
shear stress and stretching of arterial walls triggers altered
gene expression in endothelial cells (reviewed by Whyte and
Laughlin [173]). Indeed, some research groups have sug-
gested that this is what should be considered the ‘normal’
phenotype in endothelial cells, and endothelial cells in seden-
tary individuals are a deviation from the norm [173, 177, 185].
Healthy endothelial function is vital in a number of processes,
such as smooth muscle cell proliferation and migration, innate
immunity and maintaining an anti-inflammatory environment
(reviewed by Mensah [186]). Therefore, improvements in en-
dothelial function using exercise could be useful in obesity.
There is a multitude of evidence that exercise alters
adrenoceptor expression and sensitivity in cardiac tissue. In
mice, exercise training protects against myocardial reperfu-
sion injury via upregulation of β3-adrenoceptors [187].
Similarly, intense exercise in diabetic rats demonstrated in-
creased β3-adrenoceptor expression in the heart [188], al-
though a similar study using the same diabetes model, with
a less extensive training protocol, indicated improvements in
β1-adrenoceptor expression, and no effect on β2/3-
adrenoceptor expression [189]. Likewise, dogs with
ventricular fibrillation exhibited increased β1-adrenoceptor
in cardiac tissue following exercise training [190]. The effect
of exercise on adrenoceptor expression extends to immune
cells. In healthy humans, immediately after one exercise ses-
sion, β-adrenoceptor expression was increased in lympho-
cytes, although there were no studies to specify which isoform
[191]. Most importantly, for the context of this review, in the
Otsuka Long-Evans Tokushima Fatty rat, voluntary exercise
on provided exercise wheels increased β3-adrenoceptor gene
expression in adipose tissue [192].
Whilst the effects of exercise on adrenoceptor expression in
the vasculature are not well studied, there is at least some
evidence that exercise improves responsiveness of diseased
arteries. In atherosclerotic pigs, exercise improved the re-
sponse of coronary arteries to endothelin-1 [193]. In the obese
Zucker rat, exercise improved the vasodilator response of
skeletal muscle arteries to arachidonic acid, as well as improv-
ing glucose tolerance [194]. In human obese patients, exercise
improved flow-mediated dilation in both the brachial artery
and forearm microvasculature [195, 196].
Some studies have shown that exercise alters adipokine
secretion in obesity. Adiponectin is increased following exer-
cise [197], and leptin is decreased [197, 198]. In addition,
TNF-α expression is reduced in the adipose tissue of
exercised diet-induced obese mice [199]. A number of studies
have reported similar effects of exercise on inflammatory cells
in skeletal muscle. In diet-induced obesity models, forced ex-
ercise reduced TNF-α and T cell expression, macrophage in-
filtration and induced a phenotypic switch of M1 macro-
phages to M2 [200–202]. These findings were independent
of weight loss. Similarly, in a voluntary exercise study,
TNF-α expression was reduced, and this was accompanied
by improvements in insulin sensitivity and glucose tolerance
[199]. Interestingly, an acute exercise study involving only
one swimming session reduced TNF-α in adipose tissue, in-
creased M2 macrophage polarisation and improved glucose
signalling [203].
Of course we cannot exclude the role of weight loss in the
beneficial effects of exercise. Lipolysis ofWAT is regulated by
SNS, and as a result of increased energy expenditure during
exercise, lipolysis is increased [204], which will reduce fat
mass and therefore, body weight. Exercise does reduce adipo-
cyte size, and will increase mitochondrial bioavailability
[205–207], which fits with the increase in energy expenditure
required by exercise. In addition, sympathetic activation by
exercise is associated with reduced food intake [98].
The Potential for Exercise-Induced Beiging
of Adipose Tissue
As discussed previously, it is possible to stimulate white adi-
pocytes to differentiate into beige adipocytes, which may
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confer the metabolic benefits of BAT. In a recent human trial,
male obese patients were subjected to increasing periods of
mild cold exposure (which is known to induce beiging [38,
39]) whilst their dietary intake was controlled [208].
Following only 10 days, patients exhibited significant im-
provements in glucose uptake, although there were no further
studies to determine if this effect was sustained. The results of
this study, and others like it, have made beiging adipocytes an
attractive therapeutic target.
The activity of BAT is regulated by SNS [209], and as
already discussed, exercise increases SNS activity.
Therefore, it is likely that exercise will increase BAT activity.
Many exercise studies, including running and swimming,
have demonstrated that exercise stimulates beiging of WAT,
and this is true for both forced and voluntary exercise [205,
210, 211]. Interestingly, the degree of beiging, quantified by
measuring expression of uncoupling protein-1, does depend
on the duration and type of exercise (reviewed by Dewal and
Stanford [212]). Beiging appears to be much greater following
periods of swimming than running, and most surprisingly,
shorter durations of exercise (less than 3 weeks) are the most
effective. It has been suggested that exercise-induced lipoly-
sis, leading to a reduction in adipose mass [213], may become
significant during longer training programmes.
Stanford et al. [211] have conducted a particularly illumi-
nating study into the benefits of exercised-induced beiging. In
this study, exercise wheels were provided to mice for volun-
tary exercise for 11 days. Using gene set analysis, Stanford
et al. found that exercise increased expression of genes impor-
tant to glucose metabolism as well as beiging. More exciting-
ly, this group transplanted subcutaneous WAT from exercised
trained mice into the visceral cavity of sedentary high-fat diet
Fig. 2 The potential benefits of exercise on obese PVAT. Exercise is
considered healthy sympathetic nervous system (SNS) activity, and
has been shown to have multiple benefits in obesity. Lipolysis is
increased, contributing to weight loss, and exercise has been shown
to improve adrenoceptor expression in cardiac tissue. In adipose
tissue, the adipokine secretion profile is improved which will have
direct effects on the vasculature. In addition, exercise reduces
inflammation; tumour necrosis factor α (TNF-α) and interleukin-6
(IL-6) expression is reduced, and macrophages undergo a phenotyp-
ic switch to anti-inflammatory M2 macrophages. Exercise has been
shown to induce beiging of white adipose tissue, quantified by ex-
pression of uncoupling protein-1 (UCP-1). This process will enable
thermogenesis, which result in an improved metabolic profile via
increased energy expenditure
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fed mice. Whilst the fat transplant had no effect on body
weight, food intake or activity, 9 days post-transplant blood
glucose, insulin and cholesterol were significantly improved
in the high-fat diet mice. These effects were reduced 14 days
post-surgery, and completely dissipated by 28 days.
Nonetheless, these surprising results clearly demonstrate a
beneficial effect of acutely exercised fat.
A number of mechanisms behind exercise-induced beiging
and the beneficial metabolic effects have been proposedwhich
involve increased SNS activity. The simplest theory is that
exercise increases BAT activity, which results in increased
energy expenditure and therefore, weight loss [214].
Another suggestion is that exercise, or other factors which
induce beiging, may disrupt fur growth, resulting in a need
to increase thermogenesis and therefore, BAT. However, as
discussed above, exercise appears to affect adrenoceptor ex-
pression and activity, and some studies have demonstrated that
β3-adrenoceptor agonists induce beiging [215–217].
Similarly, the herbal supplement curcumin has been shown
to stimulate beiging via increasing β3-adrenoceptor expres-
sion in WAT [218], and cold-induced beiging is dependent
upon β3-adrenoceptors [219]. Therefore, it is likely that the
exercised-induced beiging mechanism involves β3-
adrenoceptors. As previously discussed, the PVAT anti-
contractile effect is dependent upon β3-adrenoceptors; there-
fore, it is possible that exercise may be useful in restoring
PVAT function in obesity via effects on β3-adrenoceptor ex-
pression and activity. For a summary of the potential effects of
SNS activation using exercise in obesity, see Fig. 2.
Summary
In addition to modulating metabolism, sympathetic nerves
in PVAT modulate the release of vasoactive factors from
adipocytes, which exert an anti-contractile effect on the
vasculature; reducing peripheral resistance and therefore,
blood pressure. Autonomic dysfunction in response to a
high-fat diet contributes to adipose tissue expansion and
recruitment of inflammatory cells in PVAT. Hypoxia and
chronic inflammation result in PVAT dysfunction, and the
overactivity of sympathetic nerves may be causing
internalisation of adipocyte adrenoceptors. Healthy sym-
pathetic hyperstimulation by exercise reduces expression
of inflammatory cells in PVAT, and may improve expres-
sion of adrenoceptors; therefore, exercise may be useful in
restoring PVAT function in obesity. In addition, exercise
may be inducing transformation of white adipocytes to
beige adipocytes, which confer an improved metabolic
phenotype. Clearly, the study of sympathetic innervation
of adipose tissue is vital to gain new insights into vascular
dysfunction in obesity.
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